DGXClinical laboratory diagnostics
Quest Diagnostics
Not investment advice. Kevin may own this stock. How we value stocks
By Kevin Amado
Updated
- Price
- $258.69
- Analysts view
- Leaning bullish
- Discount category
- Pricey
- Pick status
- Research only
- Next earnings
- Earnings Feb 9 · · estimated
- Market cap
- $28B
- Shares of Oct 15, 2026
- Yield at current rate
- 1.3%
- Current annual rate, at the price of Nov 12, 2026
- Dividend yield
- 1.3%
- Last 12 months, at the price of Nov 12, 2026
- P/E (trailing)
- 25.8
- Price of Nov 12, 2026
- EPS (trailing)
- $10.04
- 12 months to Sep 30, 2026
- 52-week range
- $171.18 – $262.00
- To Nov 12, 2026
- Beta
- 0.54
- Vs S&P 500, 5 years monthly, to Oct 30, 2026
- Average volume
- 1.0M
- 3 months, to Nov 12, 2026
Check the numbers:ExchangeGoogle FinanceYahoo FinanceSEC filings
In short
- Thesis
- The market doubts that Quest can keep double-digit volume growth and margin gains after its October data incident, and steady testing growth through 2027 can lift its value.
- Gap
- Can close. The Q4 2026 report in February 2027 and the Investor Day on March 25, 2027 show whether volume growth and margin hold after the data incident.
Company guidance: 2026 revenue $12.065 billion to $12.105 billion; adjusted EPS $11.25 to $11.35; reported EPS $10.21 to $10.31 (, Q3 2026 results release (8-K))
Price history
About
Quest Diagnostics Incorporated (Quest) provides diagnostic information services. It is based in Secaucus, New Jersey. It runs clinical laboratories and patient service centers in the United States. Quest says that it serves half the physicians and hospitals in the United States and one in three adult Americans each year.
It has nearly 60,000 employees. Net revenues were $3,097 million in Q3 2026 and $9,035 million for nine months. Requisition volume rose 14.5% in Q3 2026, and revenue per requisition fell 4.2%. Jim Davis is Chairman, Chief Executive Officer and President.
Quest formed a laboratory joint venture with Corewell Health in Michigan in January 2026. The shares trade on the NYSE in US dollars. Quest files 10-K and 10-Q reports.
Thesis
The price of Quest depends on whether volume growth of about 10% a year can continue with rising margin, and on how costly the data incident of October 2026 becomes. In Q3 2026, requisition volume rose 14.5% on strength in the physician, hospital and consumer channels, the adjusted operating margin rose to 16.7%, and adjusted earnings per share rose 15.4% to $3.00. Revenue per requisition fell 4.2%, so growth comes from volume. Quest raised its 2026 outlook in each of the first three quarters, to $11.25 to $11.35 of adjusted earnings per share.
On October 21, 2026, Quest found unauthorized access to its Quanum LSM system, and it believes that an unauthorized party accessed some patient records. For the price to hold or rise, four things must be true. Volume growth must stay near 10% as the Corewell venture and the outreach lab assets of a health system add tests. Adjusted operating margin must keep rising while revenue per requisition falls.
The incident must not bring large costs, claims or lost clients. Project Nova must stay on its plan to deploy Epic solutions in the first lab in the fall of 2027. The Q4 2026 report in February 2027 and the Investor Day on March 25, 2027 are the next tests. If growth and margin hold, the gap can close over the next year.
If the incident grows or if payers cut prices, the gap can last longer.
Checkpoints
- Feb 9, 2027 · est.PendingQ4 2026 results and 2027 outlookQuest meets its 2026 guidance of $11.25 to $11.35 of adjusted earnings per share, gives a 2027 outlook with higher earnings and shows a limited cost from the data incident, and this passes; a lower outlook or a large cost fails.
- Mar 25, 2027PendingInvestor DayQuest gives multi-year targets for volume growth and margin that match its 2026 pace, and this passes; lower targets fail.
Recent events
- October 22, 2026Quest reported Q3 2026 results. Revenues rose 10.0% to $3.10 billion, and adjusted earnings per share rose 15.4% to $3.00. Quest raised its 2026 guidance for revenue to $12.065 billion to $12.105 billion and for adjusted earnings per share to $11.25 to $11.35. It said that it will hold an Investor Day on March 25, 2027.
- October 21, 2026Quest learned of unauthorized access to its Quanum LSM system, which some clients use to place test orders and look up results. Quest said in an 8-K on October 22 that it believes an unauthorized party accessed some patient records, that the full scope is under investigation, and that the incident has not materially disrupted its business.
- October 6, 2026Quest said that Catherine T. Doherty will retire in July 2027. From November 1, 2026, she will lead health systems, the Corewell Health venture and Project Nova.
Show 3 older eventsHide older events
- July 23, 2026Quest reported Q2 2026 results. Revenues rose 10.2% to $3.04 billion, and adjusted earnings per share rose 19.1% to $3.12. Quest raised its 2026 guidance for adjusted earnings per share to $11.05 to $11.25.
- May 6, 2026Quest issued $500 million of 5.000% senior notes due 2036. It planned to use the proceeds for general purposes, including to repay $500 million of 3.45% notes that matured on June 1, 2026.
- April 21, 2026Quest reported Q1 2026 results. Revenues rose 9.2% to $2.90 billion, and adjusted earnings per share rose 13.1% to $2.50. Quest raised its 2026 guidance for adjusted earnings per share to $10.63 to $10.83.
Latest news and filings
- Last earnings
- October 22, 2026 (8-K on sec.gov)
- Next earnings
- Expected about February 9, 2027. The company has not confirmed the date.
- 10-QQuarterly report for the period ended Sep 30, 2026Filed · dgx-20260930
- 8-KOther company newsFiled · Read it on sec.gov
- 8-KEarnings releaseFiled · Press release and exhibits
- 8-KChange of directors or officersFiled · Read it on sec.gov
- 10-QQuarterly report for the period ended Jun 30, 2026Filed · dgx-20260630
- 8-KEarnings releaseFiled · Press release and exhibits
- 8-KShareholder vote resultsFiled · dgx-20260520
- 8-KNew material agreementFiled · Read it on sec.gov
- 8-KOther company newsFiled · Read it on sec.gov
- 10-QQuarterly report for the period ended Mar 31, 2026Filed · dgx-20260331
Risks
- The data incident of October 2026 can cost a lot. The full scope is under investigation. Quest still faces claims and a state attorney general investigation from the 2019 AMCA data incident, as its 10-Q says.
- Prices can fall. Revenue per requisition fell 4.2% in Q3 2026. Quest says in its 10-Q that it faces reimbursement pressures and cost increases, and its Invigorate program aims to offset them.
- Project Nova is a large change to billing and IT systems. It is a multi-year project, and Quest expects its first Epic lab in the fall of 2027. A delay or a failure can raise cost.
- Debt is moderate. Total debt was $5,550 million at September 30, 2026, against $5,671 million at December 31, 2025. Quest issued $500 million of notes in May 2026 to repay notes that matured in June 2026.
- Joint ventures and acquisitions can disappoint. Quest formed a venture with Corewell Health, in which Corewell holds 49%, and it plans to buy outreach lab assets from a health system.
Balance sheet
- Cash
- $797M
- Debt
- $5.6B
- Net debt
- $4.8B
Cash against debt
debt covered by cashnet debt $4.8B
When the debt is due
At September 30, 2026, Quest had total debt of $5,550 million, of which $10 million is current, and cash of $797 million. Net debt was $4,753 million. Debt was $5,671 million and cash was $420 million at December 31, 2025. Quest issued $500 million of 5.000% senior notes due 2036 in May 2026. Cash from operations was $1,486 million for nine months, and Quest expects about $1.90 billion for 2026 with capital expenditures of about $550 million. Quest repurchased shares for $250 million and paid dividends of $279 million in nine months, and $1.2 billion of its repurchase authorization remained. Total stockholders' equity was $7,950 million.
Dividends
- Yield at the current rate
- 1.3% (current annual rate, at today’s price)
- Dividend yield
- 1.3% (last 12 months, at today’s price of $258.69)
- Paid per share
- $3.38 in the last 12 months (4 payments)
- Current annual rate
- $3.44 ($0.86 × 4 a year)
- Payout ratio
- 36% of the last fiscal year’s earnings (the year that ended December 31, 2025)
- Latest ex-dividend date
- October 6, 2026, $0.86 per share
Dividends per share by year
| 2016 | $1.58 | |
|---|---|---|
| 2017 | $1.80 | |
| 2018 | $1.95 | |
| 2019 | $2.12 | |
| 2020 | $2.21 | |
| 2021 | $2.42 | |
| 2022 | $2.60 | |
| 2023 | $2.79 | |
| 2024 | $2.96 | |
| 2025 | $3.15 |
From 2020 to 2025, the dividend grew by about 7.3% a year. From 2015 to 2025, the dividend grew by about 7.9% a year.
Source: company filings and market data, read on November 13, 2026. The ex-dividend date is the first day a buyer no longer gets the next payment.
Questions about Quest Diagnostics
What does Quest Diagnostics do?
Quest Diagnostics Incorporated (Quest) provides diagnostic information services. It is based in Secaucus, New Jersey. Its market cap is $28B at the current price of $258.69.
When does Quest Diagnostics report earnings next?
This is an estimate: Quest Diagnostics may report on February 9, 2027. It last reported results on October 22, 2026.
Is Quest Diagnostics stock below its intrinsic value?
Quest Diagnostics stock is pricey. This is general information, not advice.
What changed recently at Quest Diagnostics?
The latest update is from October 22, 2026. Quest reported Q3 2026 results.
What are the main risks for Quest Diagnostics?
The data incident of October 2026 can cost a lot. Prices can fall. Project Nova is a large change to billing and IT systems.
How much debt and cash does Quest Diagnostics have?
At September 30, 2026, Quest Diagnostics had $5.6B of debt and $797M of cash.
Does Quest Diagnostics pay a dividend?
Yes. The current annual dividend of Quest Diagnostics is $3.44 per share. That is a dividend yield of 1.3% at the current price of $258.69. In the last 12 months, it paid $3.38 per share (1.3%). The latest ex-dividend date was October 6, 2026.
Similar companies
- RHHBYRocheShares: Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- QGENQIAGENShares: Regulation and courts
- Intrinsic value
- Close to intrinsic value
- Gap
- Can close
- ABTAbbott LaboratoriesShares: Regulation and courts
- Intrinsic value
- Pricey
- Gap
- Slow
- LHLabcorpShares: Regulation and courts
- Intrinsic value
- Pricey
- Gap
- Can close
- UNHUnitedHealth GroupShares: Regulation and courts
- Intrinsic value
- Below intrinsic value
- Gap
- Can close
Loading your notes…
Read it all? Star DGX or pass, then go on to the next one.